Antibody response of naturally infected individuals to recombinant Plasmodium vivax apical membrane antigen-1

Rodrigues, Maria Helena C.; Rodrigues, Karina Martinelli; Oliveira, Tatiane Rodrigues de; Cômodo, Andréia N.; Rodrigues, Maurício M.; Kocken, Clemens H. M.; Thomas, Alan W.; Soares, Irene S.

doi:10.1016/j.ijpara.2004.11.003

Cited by 79 publications

(108 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These responses not only were high at the active phase of the immune response (2 weeks after immunization) but also remained high for over 3 months (14 weeks) after the boost. It is worth noting that, at any time point considered, vaccination generated parasite-specific antibodies more efficiently than repeated natural human infections (45). The prime/boost protocol P/Ad described here is particularly attractive not only because it displayed higher immunogenicity but also because it could represent a significant step up in vaccine safety.…”

Section: Discussionmentioning

confidence: 95%

“…Recombinant PvAMA-1 represents a His 6 -tagged polypeptide (amino acids [aa] 43 to 487) of a P. vivax isolate from Belem, Brazil (named BEL 12), as previously described (45). Recombinant PvMSP-1 19 represents a His 6 -tagged C-terminal 19-kDa fragment (aa 1616 to 1704; GenBank accession number M60807) of Plasmodium vivax Belem strain merozoite surface protein 1.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Long-Term Humoral and Cellular Immune Responses Elicited by a Heterologous Plasmodium vivax Apical Membrane Antigen 1 Protein Prime/Adenovirus Boost Immunization Protocol

et al. 2011

Self Cite

View full text Add to dashboard Cite

Apical membrane antigen 1 (AMA-1) is an invasion-related Plasmodium antigen that is expressed during both intracellular and extracellular asexual stages of the parasite's life cycle, making it an ideal target for induction of humoral and cellular immune responses that can protect against malaria. We show here that when it is administered as a recombinant protein (P) in Montanide ISA720 adjuvant, followed by a recombinant human type 5 adenovirus (Ad), intense and long-lasting Plasmodium vivax AMA-1-specific antibody responses (including both IgG1 and IgG2a), as well as proliferative memory T cell responses, can be detected in immunized mice. Memory T cells displayed both central (CD44 hi CD62L hi ) and effector (CD44 hi CD62L lo ) phenotypes, with the central memory phenotype prevailing (56% of AMA-1-specific proliferating cells). Considering the main traits of the memory immune responses induced against AMA-1, this particular sequence of immunogens (P followed by Ad), but no others (Ad/Ad, Ad/P, or P/P), displayed an optimal synergistic effect. These results give further support to the need for preclinical studies of P. vivax vaccine candidate AMA-1 administered in prime/boost protocols that include recombinant proteins and adenoviral vectors.

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Methodsmentioning

confidence: 99%

Long-Term Humoral and Cellular Immune Responses Elicited by a Heterologous Plasmodium vivax Apical Membrane Antigen 1 Protein Prime/Adenovirus Boost Immunization Protocol

et al. 2011

Self Cite

View full text Add to dashboard Cite

show abstract

“…It seems to play a role in erythrocyte and hepatocyte invasion (Hodder et al 2001, Silvie et al 2004. A number of studies have addressed polymorphism in that PvAMA-1 encoding gene in various parts of the world, such as Asia, Oceania and South America , Figtree et al 2000, Han et al 2002, Chung et al 2003, Rodrigues et al 2005, Gunasekera et al 2007, Rajesh et al 2007, Grynberg et al 2008, Thakur et al 2008, Moon et al 2010). The PvAMA-1 protein includes three extracellular domains, known as domains I, II and III (Pizarro et al 2005) (Fig.…”

mentioning

confidence: 98%

Molecular markers and genetic diversity of Plasmodium vivax

Brito

Ferreira

2011

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

Enhanced understanding of the transmission dynamics and population genetics for Key words: malaria -Plasmodium vivax -genetic markers -genetic diversity -multiple-clone infections -microsatellitesMarkers and genetic diversity of P. vivax • Cristiana Ferreira Alves de Brito, Marcelo Urbano Ferreira 13 tual heterozygosity (H E ) values. Virtual H E is the average probability that a pair of alleles randomly obtained from the population is different. Whenever appropriate, in this review we provide H E estimates obtained using different markers for different populations.Molecular markers under selection -Until recently, most genetic markers available for characterising natural P. vivax populations were orthologues of previously identified P. falciparum antigen-coding genes. The wellcharacterised polymorphic regions in these genes have been extensively used to analyse genetic diversity patterns in P. falciparum (Roy et al. 2008). A similar approach has been explored in vivax-oriented studies (Cui et al. 2003a). The following single-copy genes in P. vivax have often been used in these studies: gam1, coding for the gametocyte antigen 1, csp, coding for the circumsporozoite protein (CSP), msp1 and msp3alpha, coding for the merozoite surface proteins (MSP)-1 and 3α, respectively, ama1, coding for the apical membrane antigen 1, and dbp, coding for the Duffy binding protein (DBP) ( Table I).A notable feature of several P. vivax surface antigens (including major vaccine-candidate molecules) is tandem arrays of relatively short amino acid motifs. The CSP in P. vivax (PvCSP), an abundant antigen on the surface of sporozoites that has been extensively used as a vaccine development target, has immunodominant B-cell epitopes that map to central repeats between nonrepetitive sequences (Nardin & Zavala 1998). PvCSP displays two major types of nonapeptide repeats [most commonly GDRA(D/A)GQPA and ANGA(G/D)(N/D)QPG], which define the variants known as VK210 and VK247, respectively (Arnot et al. 1985, Rosenberg et al. 1989 (Fig. 1). Both VK210 and VK247 variants are globally distributed, but geographic biases have been described (Cochrane et al. 1990, Qari et al. 1993a. Similar repetitive sequences are found in Brazil, Southeast Asia and Papua New Guinea (Qari et al. 1991(Qari et al. , 1992. However, markedly divergent sequence variants were found in isolates from China and North Korea (Mann et al. 1994). Although VK210 and VK247-type sequences often occur in sympatric parasite populations, there are no examples of a hybrid repeat array with both repeat types (Lim et al. 2005).A third type of repeat unit [APGANQ(E/G)GAA], identical to that described for Plasmodium simiovale, characterises the so-called P. vivax-like parasites (Qari et al. 1993a). Although P. vivax-like CSP repeats have been found in parasite isolates across the world, its global distribution remains unconfirmed (Gopinath et al. 1994). In Brazil, P. vivax-like parasites have been identified only in mixed-clone infections with VK210-type or VK247-type parasites (Machado...

show abstract

“…In previous studies, we have shown that recombinant proteins based on P. vivax AMA-1 are immunogenic in natural infection (23)(24)(25)(26). Furthermore, a prime-boost strategy using recombinant AMA-1 administered in Montanide ISA720, followed by booster injection of AdHu5 expressing PvAMA-1, produced high titers of long-lasting antibodies and specific memory T cells (27).…”

mentioning

confidence: 99%

Invasion-Inhibitory Antibodies Elicited by Immunization with Plasmodium vivax Apical Membrane Antigen-1 Expressed in Pichia pastoris Yeast

et al. 2014

Self Cite

View full text Add to dashboard Cite

h In a recent vaccine trial performed with African children, immunization with a recombinant protein based on Plasmodium falciparum apical membrane antigen 1 (AMA-1) conferred a significant degree of strain-specific resistance against malaria. To contribute to the efforts of generating a vaccine against Plasmodium vivax malaria, we expressed the ectodomain of P. vivax AMA-1 (PvAMA-1) as a secreted soluble protein in the methylotrophic yeast Pichia pastoris. Recognized by a high percentage of sera from individuals infected by P. vivax, this recombinant protein was found to have maintained its antigenicity. The immunogenicity of this protein was evaluated in mice using immunization protocols that included homologous and heterologous primeboost strategies with plasmid DNA and recombinant protein. We used the following formulations containing different adjuvants: aluminum salts (Alum), Bordetella pertussis monophosphoryl lipid A (MPLA), flagellin FliC from Salmonella enterica serovar Typhimurium, saponin Quil A, or incomplete Freund's adjuvant (IFA). The formulations containing the adjuvants Quil A or IFA elicited the highest IgG antibody titers. Significant antibody titers were also obtained using a formulation developed for human use containing MPLA or Alum plus MPLA. Recombinant PvAMA-1 produced under "conditions of good laboratory practice" provided a good yield, high purity, low endotoxin levels, and no microbial contaminants and reproduced the experimental immunizations. Most relevant for vaccine development was the fact that immunization with PvAMA-1 elicited invasioninhibitory antibodies against different Asian isolates of P. vivax. Our results show that AMA-1 expressed in P. pastoris is a promising antigen for use in future preclinical and clinical studies.

show abstract

Antibody response of naturally infected individuals to recombinant Plasmodium vivax apical membrane antigen-1

Cited by 79 publications

References 27 publications

Long-Term Humoral and Cellular Immune Responses Elicited by a Heterologous Plasmodium vivax Apical Membrane Antigen 1 Protein Prime/Adenovirus Boost Immunization Protocol

Long-Term Humoral and Cellular Immune Responses Elicited by a Heterologous Plasmodium vivax Apical Membrane Antigen 1 Protein Prime/Adenovirus Boost Immunization Protocol

Molecular markers and genetic diversity of Plasmodium vivax

Invasion-Inhibitory Antibodies Elicited by Immunization with Plasmodium vivax Apical Membrane Antigen-1 Expressed in Pichia pastoris Yeast

Contact Info

Product

Resources

About